RxDoctor Payments Data

Bonnie Skarzinski

Family · Charleston, WVNPI 1780107714

Payments from drug & device makers

$768in general payments, 2019–2025

Across 22 payments — averaging $34.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$410
  • AstraZeneca$107
  • Regeneron Healthcare Solutions, Inc.$105
  • Exact Sciences$40
  • Ironshore Pharmaceuticals Inc.$29
  • Biowound Solutions, Inc.$20
  • plus $57 from 3 others

What the payments were for

  • Food & beverage$768100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$768 in reported general payments places this provider in the 60th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$2,542
Medicare patients
28
Services billed
36

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$41,506
JanuviaSitagliptin Phosphate16$21,868
TrulicityDulaglutide17$21,712
JardianceEmpagliflozin17$20,410
MounjaroTirzepatide11$17,828
RybelsusSemaglutide13$12,415
FarxigaDapagliflozin Propanediol13$12,324
EliquisApixaban11$10,877
Albuterol Sulfate HfaAlbuterol Sulfate61$1,628
Metoprolol Succinate44$689
Gabapentin45$504
Omeprazole30$450
Pantoprazole Sodium33$435
Levothyroxine Sodium39$393
Atorvastatin Calcium37$362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$410$53,92148 claims
AstraZenecaFarxiga$107$12,32413 claims
PfizerEliquis$19$10,87711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,507 family providers in West Virginia.

Other family in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →